Ken Cacciatore
Stock Analyst at TD Cowen
(0.33)
# 4,270
Out of 5,044 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $25.29 | +97.71% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.90 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $13.77 | +45.24% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $15.47 | +126.24% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.74 | +1,236.90% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.20 | +861.54% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $18.11 | +148.48% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $16.81 | +2,636.47% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $25.29
Upside: +97.71%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.90
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $13.77
Upside: +45.24%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $15.47
Upside: +126.24%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.74
Upside: +1,236.90%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.20
Upside: +861.54%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $18.11
Upside: +148.48%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $16.81
Upside: +2,636.47%